-+ 0.00%
-+ 0.00%
-+ 0.00%

Racura Oncology's RC220 Matches RC110 Drug Exposure in Nonclinical Study

PUBT·11/17/2026 12:07:12
Listen to the news
Racura Oncology's RC220 Matches RC110 Drug Exposure in Nonclinical Study
  • Racura Oncology today announced nonclinical study results showing RC220 delivered drug exposure equivalent to its earlier RC110 formulation in dogs.
  • The findings support using RC110 clinical data and dosing levels for RC220, including in the planned Phase 2b/3 EMILI leukemia trial.
  • RC220 allows peripheral-vein administration rather than requiring a central line; it is already being tested in two early-stage cancer trials.
  • The study did not assess anticancer activity; RC220's safety and efficacy in acute myeloid leukemia remain unestablished.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Racura Oncology Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN99763) on November 17, 2026, and is solely responsible for the information contained therein.